According to Vaxcyte, Inc.’s most recent Statement Of Changes In Beneficial Ownership – Form 4 filing with the SEC dated Feb 10 07:22 PM, company Director, Hopfner Robert Lorne disclosed selling 78,158 shares at a cost of $26.53. At the time of this transaction (Feb 10), this trade was worth $2,073,658 in total. As of […]
According to Vaxcyte, Inc.’s most recent Statement Of Changes In Beneficial Ownership – Form 4 filing with the SEC dated Feb 10 07:22 PM, company Director, Hopfner Robert Lorne disclosed selling 220,744 shares at a cost of $28.19. At the time of this transaction (Feb 09), this trade was worth $6,223,692 in total. As of […]
According to Vaxcyte, Inc.’s most recent Statement Of Changes In Beneficial Ownership – Form 4 filing with the SEC dated Feb 10 07:22 PM, company Director, Hopfner Robert Lorne disclosed selling 79,796 shares at a cost of $25.79. At the time of this transaction (Feb 08), this trade was worth $2,058,117 in total. As of […]
According to Crocs, Inc.’s most recent Statement Of Changes In Beneficial Ownership – Form 4 filing with the SEC dated Feb 10 07:19 PM, company Chief Executive Officer, Rees Andrew disclosed selling 40,000 shares at a cost of $80.35. At the time of this transaction (Feb 09), this trade was worth $3,214,000 in total. As […]
According to Rimini Street, Inc.’s most recent Statement Of Changes In Beneficial Ownership – Form 4 filing with the SEC dated Feb 10 07:19 PM, company EVP, CLO & Corp. Sec., Winslow Daniel B. disclosed selling 10,000 shares at a cost of $8.57. At the time of this transaction (Feb 10), this trade was worth […]
According to Rimini Street, Inc.’s most recent Statement Of Changes In Beneficial Ownership – Form 4 filing with the SEC dated Feb 10 07:19 PM, company EVP, CLO & Corp. Sec., Winslow Daniel B. disclosed selling 10,000 shares at a cost of $7.98. At the time of this transaction (Feb 08), this trade was worth […]
According to Trillium Therapeutics Inc.’s most recent Statement Of Changes In Beneficial Ownership – Form 4 filing with the SEC dated Feb 10 07:18 PM, company Chief Development Officer, Petrova Penka disclosed selling 508 shares at a cost of $14.17. At the time of this transaction (Feb 09), this trade was worth $7,200 in total. […]
According to Trillium Therapeutics Inc.’s most recent Statement Of Changes In Beneficial Ownership – Form 4 filing with the SEC dated Feb 10 07:18 PM, company Chief Development Officer, Petrova Penka disclosed selling 5,312 shares at a cost of $12.65. At the time of this transaction (Feb 08), this trade was worth $67,197 in total. […]
According to Trillium Therapeutics Inc.’s most recent Statement Of Changes In Beneficial Ownership – Form 4 filing with the SEC dated Feb 10 07:18 PM, company Chief Scientific Officer, Uger Robert disclosed selling 584 shares at a cost of $14.12. At the time of this transaction (Feb 09), this trade was worth $8,248 in total. […]
According to Trillium Therapeutics Inc.’s most recent Statement Of Changes In Beneficial Ownership – Form 4 filing with the SEC dated Feb 10 07:18 PM, company Chief Scientific Officer, Uger Robert disclosed selling 6,563 shares at a cost of $12.65. At the time of this transaction (Feb 08), this trade was worth $83,022 in total. […]
PayPal Withdrawing Support For Kindle Fire, BlackBerry And Windows Phone
Revival Of Nashville Discussed
Brawl Erupts After Jose Bautista Downed By Rougned Odor Punch
VR Tour Offered Three Decades After Chernobyl Disaster
Kyle Busch Sweeps NASCAR Events At Martinsville
Halle Berry Enters The Social Media World
